select a format

Single User License
USD 2000 INR 129980
Site License
USD 4000 INR 259960
Corporate User License
USD 6000 INR 389940

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline Review, H2 2015

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline Review, H2 2015


  • Products Id :- GMDHC7211IDB
  • |
  • Pages: 374
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline Review, H2 2015', provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 10

Therapeutics Development 11

Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Overview 11

Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Comparative Analysis 12

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Therapeutics under Development by Companies 13

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Therapeutics under Investigation by Universities/Institutes 17

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Products under Development by Companies 21

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Products under Investigation by Universities/Institutes 26

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Companies Involved in Therapeutics Development 27

AB Science SA 27

AbbVie Inc. 28

Adamis Pharmaceuticals Corporation 29

Advaxis, Inc. 30

Ambrx, Inc. 31

Amgen Inc. 32

Arrowhead Research Corporation 33

AstraZeneca Plc 34

ATLAB Pharma SAS 35

Bavarian Nordic A/S 36

BIND Therapeutics, Inc. 37

Boehringer Ingelheim GmbH 38

Bristol-Myers Squibb Company 39

CellCentric Ltd 40

CureVac GmbH 41

DexTech Medical AB 42

Eli Lilly and Company 43

Emergent BioSolutions Inc. 44

F. Hoffmann-La Roche Ltd. 45

Genentech, Inc. 46

GenSpera, Inc. 47

GlaxoSmithKline Plc 48

GTx, Inc. 49

Johnson & Johnson 50

Karyopharm Therapeutics, Inc. 51

Medivation, Inc. 52

Millennium Pharmaceuticals, Inc. 53

NewLink Genetics Corporation 54

Novartis AG 55

Oncogenex Pharmaceuticals, Inc. 56

Oncolytics Biotech Inc. 57

Onyx Pharmaceuticals, Inc. 58

Orion Oyj 59

Pfizer Inc. 60

Progenics Pharmaceuticals, Inc. 61

Sanofi 62

Sotio a.s. 63

Sun Pharma Advanced Research Company Ltd. 64

Supratek Pharma Inc. 65

Taiho Pharmaceutical Co., Ltd. 66

Takeda Pharmaceutical Company Limited 67

Tesaro, Inc. 68

Tokai Pharmaceuticals, Inc. 69

TRACON Pharmaceuticals, Inc. 70

Viralytics Ltd. 71

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Therapeutics Assessment 72

Assessment by Monotherapy Products 72

Assessment by Target 73

Assessment by Mechanism of Action 77

Assessment by Route of Administration 80

Assessment by Molecule Type 82

Drug Profiles 84

abiraterone acetate-Drug Profile 84

ABS-001-Drug Profile 87

Adipotide-Drug Profile 88

ADXS-PSA-Drug Profile 89

afuresertib hydrochloride-Drug Profile 91

apatorsen-Drug Profile 93

APC-200-Drug Profile 95

APC-300-Drug Profile 96

ASN-001-Drug Profile 97

ATL-101-Drug Profile 98

AZD-5312-Drug Profile 100

AZD-5363-Drug Profile 101

BI-836845-Drug Profile 103

BMTP-11-Drug Profile 105

cabazitaxel-Drug Profile 106

cabazitaxel-Drug Profile 108

carfilzomib-Drug Profile 109

Cell Therapy to Target PSMA for Metastatic Hormone Refractory Prostate Cancer-Drug Profile 113

crizotinib-Drug Profile 114

custirsen sodium-Drug Profile 118

CV-9103-Drug Profile 122

CVA-21-Drug Profile 123

Dendritic Cell Therapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer-Drug Profile 127

docetaxel-Drug Profile 128

docetaxel-Drug Profile 130

emibetuzumab-Drug Profile 131

enzalutamide-Drug Profile 132

erismodegib-Drug Profile 135

ES-414-Drug Profile 138

everolimus-Drug Profile 139

galeterone-Drug Profile 145

GSK-2636771-Drug Profile 147

GTx-758-Drug Profile 148

idasanutlin-Drug Profile 150

indoximod-Drug Profile 152

JNJ-56021927-Drug Profile 154

lirilumab-Drug Profile 156

LY-3022855-Drug Profile 158

LY-3023414-Drug Profile 159

masitinib-Drug Profile 161

mipsagargin-Drug Profile 166

Monoclonal Antibody Drug Conjugate to Inhibit PSMA for GBM and CRPC-Drug Profile 168

MVI-816-Drug Profile 169

navitoclax dihydrochloride-Drug Profile 171

niraparib-Drug Profile 173

ODM-201-Drug Profile 175

ODM-204-Drug Profile 177

olaparib-Drug Profile 178

olaratumab-Drug Profile 182

ONC-113B-Drug Profile 184

Osteodex-Drug Profile 185

pelareorep-Drug Profile 186

Protein for Prostate Cancer-Drug Profile 191

PSMA ADC-Drug Profile 192

rilimogene galvacirepvec-Drug Profile 194

rilotumumab-Drug Profile 197

sapanisertib-Drug Profile 199

selinexor-Drug Profile 201

Small Molecule to Antagonize Androgen Receptor for Prostate Cancer-Drug Profile 207

Small Molecules to Antagonize Androgen Receptor for Metastatic Castration Resistant Prostate Cancer-Drug Profile 208

Small Molecules to Antagonize Androgen Receptors for Metastatic Hormone Refractory Prostate Cancer-Drug Profile 209

Small Molecules to Inhibit Bromodomain for Prostate Cancer-Drug Profile 210

Small Molecules to Inhibit Deubiquitinase for Castrate Resistant Prostate Cancer-Drug Profile 211

stapuldencel-t-Drug Profile 212

TAS-3681-Drug Profile 214

TL-118-Drug Profile 215

TRC-105-Drug Profile 217

Vaccine for Prostate Cancer-Drug Profile 220

Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer-Drug Profile 223

vandortuzumab vedotin-Drug Profile 225

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Recent Pipeline Updates 226

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects 352

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Discontinued Products 356

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Product Development Milestones 357

Featured News & Press Releases 357

Appendix 368

Methodology 368

Coverage 368

Secondary Research 368

Primary Research 368

Expert Panel Validation 368

Contact Us 368

Disclaimer 369

List of Tables

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2015 16

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Comparative Analysis, H2 2015 17

Number of Products under Development by Companies, H2 2015 19

Number of Products under Development by Companies, H2 2015 (Contd...1) 20

Number of Products under Development by Companies, H2 2015 (Contd...2) 21

Number of Products under Investigation by Universities/Institutes, H2 2015 22

Comparative Analysis by Late Stage Development, H2 2015 23

Comparative Analysis by Clinical Stage Development, H2 2015 24

Comparative Analysis by Early Stage Development, H2 2015 25

Products under Development by Companies, H2 2015 26

Products under Development by Companies, H2 2015 (Contd...1) 27

Products under Development by Companies, H2 2015 (Contd...2) 28

Products under Development by Companies, H2 2015 (Contd...3) 29

Products under Development by Companies, H2 2015 (Contd...4) 30

Products under Investigation by Universities/Institutes, H2 2015 31

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by AB Science SA, H2 2015 32

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by AbbVie Inc., H2 2015 33

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Adamis Pharmaceuticals Corporation, H2 2015 34

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Advaxis, Inc., H2 2015 35

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Ambrx, Inc., H2 2015 36

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Amgen Inc., H2 2015 37

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Arrowhead Research Corporation, H2 2015 38

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by AstraZeneca Plc, H2 2015 39

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by ATLAB Pharma SAS, H2 2015 40

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Bavarian Nordic A/S, H2 2015 41

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by BIND Therapeutics, Inc., H2 2015 42

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2015 43

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Bristol-Myers Squibb Company, H2 2015 44

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by CellCentric Ltd, H2 2015 45

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by CureVac GmbH, H2 2015 46

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by DexTech Medical AB, H2 2015 47

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Eli Lilly and Company, H2 2015 48

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Emergent BioSolutions Inc., H2 2015 49

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 50

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Genentech, Inc., H2 2015 51

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by GenSpera, Inc., H2 2015 52

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by GlaxoSmithKline Plc, H2 2015 53

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by GTx, Inc., H2 2015 54

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Johnson & Johnson, H2 2015 55

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Karyopharm Therapeutics, Inc., H2 2015 56

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Medivation, Inc., H2 2015 57

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 58

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by NewLink Genetics Corporation, H2 2015 59

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Novartis AG, H2 2015 60

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2015 61

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Oncolytics Biotech Inc., H2 2015 62

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 63

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Orion Oyj, H2 2015 64

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Pfizer Inc., H2 2015 65

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Progenics Pharmaceuticals, Inc., H2 2015 66

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Sanofi, H2 2015 67

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Sotio a.s., H2 2015 68

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 69

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Supratek Pharma Inc., H2 2015 70

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2015 71

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 72

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Tesaro, Inc., H2 2015 73

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Tokai Pharmaceuticals, Inc., H2 2015 74

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by TRACON Pharmaceuticals, Inc., H2 2015 75

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Pipeline by Viralytics Ltd., H2 2015 76

Assessment by Monotherapy Products, H2 2015 77

Number of Products by Stage and Target, H2 2015 79

Number of Products by Stage and Mechanism of Action, H2 2015 83

Number of Products by Stage and Route of Administration, H2 2015 86

Number of Products by Stage and Molecule Type, H2 2015 88

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics-Recent Pipeline Updates, H2 2015 231

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects, H2 2015 357

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects (Contd..1), H2 2015 358

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects (Contd..2), H2 2015 359

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Dormant Projects (Contd..3), H2 2015 360

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Discontinued Products, H2 2015 361

List of Figures

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2015 16

Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Comparative Analysis, H2 2015 17

Number of Products under Development by Companies, H2 2015 18

Number of Products under Investigation by Universities/Institutes, H2 2015 22

Comparative Analysis by Clinical Stage Development, H2 2015 24

Comparative Analysis by Early Stage Products, H2 2015 25

Assessment by Monotherapy Products, H2 2015 77

Number of Products by Top 10 Targets, H2 2015 78

Number of Products by Stage and Top 10 Targets, H2 2015 78

Number of Products by Top 10 Mechanism of Actions, H2 2015 82

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 82

Number of Products by Top 10 Routes of Administration, H2 2015 85

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 85

Number of Products by Top 10 Molecule Types, H2 2015 87

Number of Products by Stage and Top 10 Molecule Types, H2 2015 87

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science SA

AbbVie Inc.

Adamis Pharmaceuticals Corporation

Advaxis, Inc.

Ambrx, Inc.

Amgen Inc.

Arrowhead Research Corporation

AstraZeneca Plc

ATLAB Pharma SAS

Bavarian Nordic A/S

BIND Therapeutics, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

CellCentric Ltd

CureVac GmbH

DexTech Medical AB

Eli Lilly and Company

Emergent BioSolutions Inc.

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

GenSpera, Inc.

GlaxoSmithKline Plc

GTx, Inc.

Johnson & Johnson

Karyopharm Therapeutics, Inc.

Medivation, Inc.

Millennium Pharmaceuticals, Inc.

NewLink Genetics Corporation

Novartis AG

Oncogenex Pharmaceuticals, Inc.

Oncolytics Biotech Inc.

Onyx Pharmaceuticals, Inc.

Orion Oyj

Pfizer Inc.

Progenics Pharmaceuticals, Inc.

Sanofi

Sotio a.s.

Sun Pharma Advanced Research Company Ltd.

Supratek Pharma Inc.

Taiho Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Company Limited

Tesaro, Inc.

Tokai Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc.

Viralytics Ltd.

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Products under Development, Key Players in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Overview, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com